Orchestra BioMed Cash And Short Term Investments Over Time
| OBIO Stock | 5.64 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Orchestra BioMed Performance and Orchestra BioMed Correlation. Orchestra |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cash And Short Term Investments Analysis
Compare Orchestra BioMed Holdings and related stocks such as CytomX Therapeutics, Assembly Biosciences, and Achilles Therapeutics PLC Cash And Short Term Investments Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTMX | 8.7 M | 8.7 M | 8.7 M | 8.7 M | 64.4 M | 186.7 M | 181.9 M | 374.1 M | 436.1 M | 296.1 M | 316.1 M | 305.2 M | 193.7 M | 174.5 M | 253.8 M |
| ASMB | 15.9 K | 37 M | 20.5 M | 27.1 M | 29.1 M | 67.7 M | 53 M | 119.9 M | 218.1 M | 274 M | 216.4 M | 146.6 M | 91.6 M | 130.2 M | 99.4 M |
| ACHL | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 97.6 M | 177.8 M | 266.3 M | 173.3 M | 131.5 M | 186.3 M |
| TIL | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 241.7 M | 454.1 M | 260.9 M | 150.4 M | 245.5 M |
| NXTC | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 135.2 M | 334.6 M | 283.4 M | 219.6 M | 159.9 M | 108.3 M | 196.3 M |
| SPRO | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M | 10.3 M | 87.3 M | 115.4 M | 82 M | 126.9 M | 146.4 M | 109.1 M | 76.3 M | 92.8 M |
| NUVB | 118.9 M | 118.9 M | 118.9 M | 118.9 M | 118.9 M | 118.9 M | 118.9 M | 118.9 M | 118.9 M | 118.9 M | 215.8 M | 765.4 M | 661 M | 611.2 M | 521.9 M |
| CGEM | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | 98.6 M | 210.2 M | 430.9 M | 550.1 M | 467.1 M | 328.3 M |
| BOLT | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 34.8 M | 22.8 M | 186.2 M | 168.9 M | 102.2 M | 96.9 M |
| DAWN | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 43.7 M | 284.3 M | 342.3 M | 366.3 M | 234.1 M |
Orchestra BioMed Holdings and related stocks such as CytomX Therapeutics, Assembly Biosciences, and Achilles Therapeutics PLC Cash And Short Term Investments description
Short Term Investments is an account in the current assets section of Orchestra BioMed Holdings balance sheet. This account contains Orchestra BioMed investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Orchestra BioMed Holdings fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.My Equities
My Current Equities and Potential Positions
| Orchestra BioMed Holdings | OBIO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
null 5.64
Check out Orchestra BioMed Performance and Orchestra BioMed Correlation. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Orchestra BioMed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.